A Multicenter Randomized Phase III Study of Pemetrexed Versus Erlotinib in Patients With Pretreated Advanced Non-Small-Cell Lung Cancer (NSCLC)
This trial will compare the efficacy of pemetrexed versus erlotinib in pretreated patients
with advanced NSCLC.
Interventional
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Time to Tumor Progression
1 year TTP
No
Lampros Vamvakas, MD
Principal Investigator
University Hospital of Crete
Greece: National Organization of Medicines
CT/06.05
NCT00440414
April 2006
April 2010
Name | Location |
---|